HeartSciences (NASDAQ:HSCS – Free Report) had its target price trimmed by Ascendiant Capital Markets from $15.00 to $9.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock.
Separately, Wall Street Zen raised shares of HeartSciences to a “sell” rating in a report on Saturday, July 26th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $10.50.
Get HeartSciences alerts:
Check Out Our Latest Analysis on HSCS
HeartSciences Trading Up 2.6%
HSCS opened at $3.57 on Wednesday. HeartSciences has a twelve month low of $2.52 and a twelve month high of $6.47. The stock has a market cap of $9.46 million, a PE ratio of -0.43 and a beta of 2.57. The business’s 50 day moving average is $3.49 and its 200-day moving average is $3.52.
HeartSciences (NASDAQ:HSCS – Get Free Report) last announced its earnings results on Thursday, September 11th. The company reported ($1.58) earnings per share for the quarter, beating the consensus estimate of ($2.41) by $0.83. As a group, analysts forecast that HeartSciences will post -10.01 EPS for the current year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in HeartSciences stock. Astoria Strategic Wealth Inc. bought a new stake in HeartSciences Inc. (NASDAQ:HSCS – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 18,927 shares of the company’s stock, valued at approximately $53,000. Astoria Strategic Wealth Inc. owned 1.75% of HeartSciences at the end of the most recent quarter. Institutional investors own 17.24% of the company’s stock.
About HeartSciences
(Get Free Report)
Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor’s offices, urgent care centers, and hospitals.
Further Reading
Five stocks we like better than HeartSciences
3 Stocks to Consider Buying in October
Datavault AI: The New AI Contender Backed by Big Funding
A Deeper Look at Bid-Ask Spreads
CoreWeave: Why the New King of AI Infrastructure Has Room to Run
Financial Services Stocks Investing
Top 3 Dividend Achievers for October: High Yields, Growth Ahead